Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Pig kidney xenotransplantation offers a bridge for patients awaiting human donor kidneys

In January 2026, Tim Andrews, who had received a genetically edited pig kidney in January 2025, became the recipient of a human kidney.

3 Sep 2026

New injectable microgel system delivers precise radiation to keloids

Researchers in Korea are developing a new approach to localized brachytherapy that could improve the treatment of keloid scars.

27 Aug 2026

Antibodies for visualizing cell identity and tumor architecture

Whether you are characterizing cell state transitions, assessing organelle integrity, or building a multiplex immunofluorescence (IF) assay, you need reliable structural markers for your imaging.

From Antibodies Incorporated 21 Aug 2026

Study links delayed Ewing sarcoma growth to reduced Trk and IGF1R pathway markers

A new research paper was published in Volume 17 of Oncotarget on August 7, 2026, titled "Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers."

10 Aug 2026

New therapy targets Hippo pathway to fight treatment-resistant acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.

13 Jul 2026

Feeder-free TIL expansion system makes advanced cancer immunotherapy safer

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

3 Jul 2026

Tailored drug combinations improve outcomes for treatment-resistant advanced melanoma

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.

2 Jul 2026

Study validates research models for tracking circular extra-chromosomal DNA

Damage to DNA in cancer cells can lead to pieces breaking off chromosomes and floating away, like icebergs cracking off from a glacier.

5 Jun 2026

Study shows how TAF1 regulates ferroptosis in cancer cells

Ferroptosis has become a promising area in cancer research because it may provide a way to target tumor cells that evade other better-known forms of programmed cell death, such as apoptosis and necroptosis.

3 Jun 2026

New PET tracer offers a powerful tool for kidney cancer staging

A new PET tracer targeting carbonic anhydrase IX (CAIX) has demonstrated exceptional sensitivity and high tumor-to-background contrast in detecting clear cell renal cell carcinoma (ccRCC), according to early clinical research.

1 Jun 2026

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes an NSCLC‑directed, hypoxia‑responsive AAV platform that integrates MGS4 peptide‑guided capsid targeting with dual hypoxia‑responsive element (HRE)‑gated promoters driving Q‑CXCL9‑Fc (chemokine) and miR‑30‑based shRNA against mesothelin (MSLN).

1 Jun 2026

Glycocalyx modification boosts immune cell targeting against B lymphoma

A new study published in Engineering provides mechanistic insights into live-cell glycocalyx engineering and supports the rational design of next-generation adoptive cell therapies (ACTs) against B lymphoma, addressing limitations such as high costs and restricted antigen specificity in current treatments.

25 Apr 2026

Insilico Medicine nominates AI-driven drug candidate for cancer, Cushing's syndrome and obesity

The NR3C1 (nuclear receptor subfamily 3 group C member 1) gene encodes the glucocorticoid receptor (GR), a nuclear receptor vital for maintaining physiological homeostasis, and inhibition of NR3C1 could increase the sensitivity of cancer cells to standard chemotherapy, particularly in ovarian cancer.

8 Apr 2026

Study reveals how hyperdiploidy creates rare pre-leukemic clones in children

B-cell acute lymphoblastic leukemia is the most common form of childhood cancer. In this type of cancer, which affects blood cells, one of the most common abnormalities is the presence of cells with an excess of chromosomes (hyperdiploidy), a condition that leads to chromosomal instability.

8 Apr 2026

Blocking nitric oxide suppresses tumor growth in aggressive pediatric neuroblastoma

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born harboring a malignancy that may not declare itself for months.

7 Apr 2026

New strategy exploits specific genetic vulnerability in colorectal cancer patients

Researchers have identified a novel therapeutic approach for colorectal cancer by exploiting a specific genetic vulnerability found in a majority of patients.

6 Apr 2026

$Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia$

Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T cells to target specific antigens on leukemia cells, with the goal of identifying and eliminating them.

9 Mar 2026

MSK uncovers how interacting mutations shield breast cancer

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in breast cancer patients can interact and drive resistance to certain drugs called CDK4/6 inhibitors. This finding, published in Nature, suggests a new strategy for predicting and preventing resistance to specific therapies based on the tumor's genetic profile.

6 Mar 2026

Mussel-inspired adhesive prevents organ rejection

A new technology has been developed to suppress immune rejection, the biggest challenge in organ transplantation, without causing systemic side effects. A research team from Pohang University of Science and Technology (POSTECH) and Ewha Womans University has developed the "Immune-Shield" technology, which directly sprays immunosuppressants onto the surface of organs using mussel-derived adhesive protein.